Boston Scientific 8-K

PositiveEarningsNew guidance

MiRus investment secures an exclusive option to acquire its TAVR business; accelerated share repurchase completed.

Filed 2026-07-29 06:33 ET

Summary

Q2 2026 results with Q3 and FY2026 guidance. Net sales grew 7.5% reported and 7.0% operational and organic; GAAP net income attributable to Boston Scientific common stockholders and adjusted EPS increased Y/Y. The company also completed its $2B share repurchase program and made a $1.5B investment in MiRus.

Key Figures

Metric Q2 2026 Q2 2025 Y/Y
Net sales $5.44B $5.06B 7.5%
Operating income $1.18B $819M 43.8%
Net income attributable to Boston Scientific common stockholders $907M $797M 13.8%
Diluted EPS $0.61 $0.53 15.1%
Adjusted EPS, non-GAAP $0.86 $0.75 14.7%
  • Sales growth was at the top of the company’s Q2 guidance ranges; adjusted EPS was above its Q2 guidance range of $0.82-$0.84. Cardiovascular sales grew 8.3% reported and 7.8% operational and organic; MedSurg grew 5.9% and 5.4%, respectively.
  • Completed the $2B accelerated share repurchase, repurchasing approximately 40M shares. Diluted weighted-average shares fell 1.25% Y/Y, from 1.49B to 1.47B.
  • Invested $1.5B in MiRus for an approximately 34% equity stake and an exclusive option to acquire its TAVR business.

Guidance

Metric Period Guidance Prior Direction
Reported net sales growth Q3 2026 3%-5% Y/Y — —
Organic net sales growth Q3 2026 3%-5% Y/Y — —
Adjusted EPS, non-GAAP Q3 2026 $0.80-$0.82 — —
Reported net sales growth FY2026 ≈5.5%-6.5% Y/Y — —
Organic net sales growth FY2026 5%-6% Y/Y — —
Adjusted EPS, non-GAAP FY2026 $3.28-$3.32 — —

Investor Takeaways

  • Q3 and FY2026 reported and organic sales growth and adjusted EPS will show performance against the company’s outlook.
  • Watch the pivotal FARADIGM trial of the FARAFLEX mapping and pulsed field ablation catheter; enrollment has begun, and the device remains investigational.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback